Aurinia Pharmaceuticals Inc. (AUPH) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Aurinia Pharmaceuticals Inc. (AUPH): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 78/100 — a percentile rank of Aurinia Pharmaceuticals Inc.’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.
| Market cap | $2.2B |
| P / E | 6.9× |
| P / S | 6.9× |
| EV / EBITDA | 13.0× |
| Gross margin | 90.4% |
| Operating margin | 44.0% |
| Net margin | 100.8% |
| Return on equity | 51.1% |
| ROIC | 54.2% |
| Revenue growth | 19.8% |
| Debt / equity | 0.1× |
| Dividend yield | 0.0% |
Is Aurinia Pharmaceuticals Inc. overvalued? P/S looks fair vs its 5-year range; P/B looks fair vs its 5-year range.
Independent of the events above — derived from Aurinia Pharmaceuticals Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact